Profil
Inger Sandlie is the founder of Nykode Therapeutics ASA, founded in 2006, and Nextera AS, founded in 2009.
At Nextera AS, she held the title of Scientific Advisor.
Currently, Dr. Sandlie holds the position of Director at Radiumhospitalets Forskningsstiftelse and the title of Professor at the University of Oslo.
Aktive Positionen von Inger Sandlie
| Unternehmen | Position | Beginn |
|---|---|---|
Radiumhospitalets Forskningsstiftelse
Radiumhospitalets Forskningsstiftelse Financial ConglomeratesFinance Invests in companies from Nordic research institutions | Direktor/Vorstandsmitglied | - |
University of Oslo
University of Oslo Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Inger Sandlie
| Unternehmen | Position | Ende |
|---|---|---|
| NYKODE THERAPEUTICS | Gründer | - |
Nextera AS
Nextera AS Miscellaneous Commercial ServicesCommercial Services Provides drug research for therapeutic interventions for autoimmune diseases, chronic infections, and cancer | Gründer | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Radiumhospitalets Forskningsstiftelse
Radiumhospitalets Forskningsstiftelse Financial ConglomeratesFinance Invests in companies from Nordic research institutions | Finance |
University of Oslo
University of Oslo Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Nykode Therapeutics ASA
Nykode Therapeutics ASA Pharmaceuticals: MajorHealth Technology Develops vaccines and immunotherapy against infectious diseases and cancer | Health Technology |
Nextera AS
Nextera AS Miscellaneous Commercial ServicesCommercial Services Provides drug research for therapeutic interventions for autoimmune diseases, chronic infections, and cancer | Commercial Services |
















